InterCure Ltd. (NASDAQ:INCR – Get Free Report) was up 1% during trading on Monday . The stock traded as high as $2.16 and last traded at $2.03. Approximately 70,464 shares traded hands during trading, a decline of 4% from the average daily volume of 73,210 shares. The stock had previously closed at $2.01.
InterCure Price Performance
The company has a market cap of $96.61 million, a PE ratio of 16.31 and a beta of 1.51. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.85 and a quick ratio of 1.38. The stock’s 50-day moving average is $2.75 and its 200 day moving average is $2.15.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in InterCure stock. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of InterCure Ltd. (NASDAQ:INCR – Free Report) by 31.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,140,977 shares of the company’s stock after buying an additional 271,080 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in InterCure were worth $1,460,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 8.34% of the company’s stock.
About InterCure
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
See Also
- Five stocks we like better than InterCure
- Market Cap Calculator: How to Calculate Market Cap
- AbbVie Stock: A Perfect Dip for Investors to Buy
- Trading Stocks: RSI and Why it’s Useful
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for InterCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterCure and related companies with MarketBeat.com's FREE daily email newsletter.